MARKET

BLUE

BLUE

Bluebird Bio Inc
NASDAQ
1.255
-0.095
-7.04%
Opening 10:57 07/17 EDT
OPEN
1.310
PREV CLOSE
1.350
HIGH
1.370
LOW
1.230
VOLUME
2.44M
TURNOVER
0
52 WEEK HIGH
5.53
52 WEEK LOW
0.8450
MARKET CAP
241.89M
P/E (TTM)
-1.6855
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BLUE last week (0708-0712)?
Weekly Report · 2d ago
Bluebird Bio (BLUE) Gets a Buy from Bank of America Securities
TipRanks · 07/10 13:17
Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management
Seeking Alpha · 07/09 16:31
Weekly Report: what happened at BLUE last week (0701-0705)?
Weekly Report · 07/08 09:11
bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)
Bluebird bio, Inc. Granted stock options to its chief financial officer, James Sterling, to purchase 300,000 shares of common stock. The stock options vest over four years. Bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.
Barchart · 07/03 15:05
Weekly Report: what happened at BLUE last week (0624-0628)?
Weekly Report · 07/01 09:11
What's Next For Alnylam Stock After A 60% Rise In A Week?
NASDAQ · 06/30 17:40
bluebird bio's Flight Through Financial Fog And Fierce Rivals
Seeking Alpha · 06/27 19:21
More
About BLUE
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).

Webull offers bluebird bio Inc stock information, including NASDAQ: BLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BLUE stock methods without spending real money on the virtual paper trading platform.